Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the Potential of Precision-Delivered Noninvasive Neurostimulation Treatment for Mild-to-Moderate Alzheimer’s Disease Phase II sham-controlled randomized trial met its primary endpoint with statistical significance; treatment slowed cognitive decline by 82% over 6 months in the treated population compared to sham...

Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and functional decline in Alzheimer’s disease patients Breakthrough...